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Recent work has illuminated three critical aspects of the cell biology of HIV-1 particle genesis. First, we have
come to understandwhich cellular membranes are selected as platforms for virus particle assembly and how
this occurs. Second, an understanding of how the host ESCRT pathway enables virion budding is accruing.
Third, it has become apparent that a host inhibitor can block HIV-1 particle release and that antagonism of
this inhibitor underlies the ability of HIV and SIV accessory genes to facilitate particle release. Here, I review
recent progress in these three areas.Introduction
In the 25 years since its discovery, HIV-1 has taught us much
about the biology of its host cells. Similarly, an understanding
of cell biology has helped illuminate numerous virological
processes, such as viral entry and viral gene expression, as
well as themechanisms bywhich HIV-1 accessory genesmanip-
ulate the host cell to facilitate virus replication (Ho and Bieniasz,
2008). One of the more complex and interesting steps of the HIV
life cycle, which is intricately connected to host cell biology, is
the generation of new HIV-1 particles by infected cells. Conse-
quently, the study of HIV-1 particle assembly, budding, and
release has been especially rich in terms of the exchange of
concepts and techniques with related areas of cell biology.While
there remain some significant gaps in our understanding of how
HIV-1 particles are constructed, recent progress in this area has
been significant. Here, I review recent developments in three
aspects of HIV-1 assembly, each of which involve specific inter-
actions with components of the host cell, and inwhich there have
been significant recent conceptual advances.
The HIV-1 Gag Protein
The Gag protein is central to the assembly of HIV-1 and all other
retroviruses. In most cases, its expression as the only viral
protein in appropriate cells is sufficient to generate extracellular
virus-like particles (VLPs) that are morphologically indistinguish-
able from bona fide immature virions. It is even possible to link
Gag to fluorescent proteins, which can be placed at internal or
C-terminal locations to generate fusion proteins that assemble
and are released from cells as efficiently as authentic Gag
proteins. Accurate particle morphology often requires coexpres-
sion of unfused Gag, but if this precaution is taken, Gag-GFP
fusion proteins accurately report the location of Gag during
particle morphogenesis (Larson et al., 2005). These properties
have proven extremely useful in studies of the cell biology
HIV-1 particle morphogenesis, and it is now possible to visualize
the movement of Gag and the assembly of virions in real time
(Gomez and Hope, 2006; Jouvenet et al., 2008; Larson et al.,
2005).
The functional organization of the HIV-1 Gag protein is fairly
typical of that of other retroviruses (Figure 1A). An N-terminal
MA (matrix) domain, which consists of an N-terminally myristoy-
lated globular head and a largely a-helical stalk, is responsible550 Cell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc.for directing Gag to cell membranes. A central CA (capsid)
domain homo-oligomerizes in an ordered manner during
assembly and is a critical determinant of particle morphology.
The NC (nucleocapsid) domain binds RNA, enabling the pack-
aging of the viral genome, and simultaneous interactions
between a single RNA molecule and multiple Gag molecules
help to drive Gag multimerization. Finally, a C-terminal domain,
termed p6, may be largely unstructured but contains short-
peptide docking sites for the ESCRT and ESCRT-associated
proteins that are required for the separation of the virion enve-
lope from host cell membranes. Each of these protein domains
and their associated activities are required for the efficient gener-
ation of immature extracellular viral particles. While expression
of the intact HIV-1 Gag molecule is sufficient for the generation
of immature particles, the viral protease catalyzes a series of
cleavage events in Gag during and/or after budding that results
in a striking series of structural and morphological changes,
particularly in CA domain that will form the viral capsid, that
are required for particles to be infectious. The properties of the
HIV-1 Gag protein and the structural biology of the rearrange-
ments that accompany particle maturation have been recently
and comprehensively reviewed elsewhere (Adamson and Freed,
2007; Ganser-Pornillos et al., 2008; Klein et al., 2007; Morita and
Sundquist, 2004).
Gag ‘‘Transport’’ in Cells and Selection of Sites
for Particle Assembly
In basic terms, the generation of an HIV-1 Gag VLP or an imma-
ture virion consists of the formation of a Gag protein sphere
within a lipid bilayer envelope. In cells, the HIV-1 Gag protein
sphere, visible by electron microscopy, forms only on the cyto-
plasmic face of a cell membrane, such that assembly and envel-
opment of the sphere are simultaneous processes (Figure 1B).
This is not true of all retroviruses—for some (e.g., Mason Pfizer
monkey virus [MPMV]), protein spheres assemble in the cyto-
plasm and then move to membranes where they are enveloped.
Thus, two apparently distinct pathways for the early steps of
retrovirus particle morphogenesis exist. However, it is relatively
straightforward to convert the morphogenesis pathway of
MPMV to one that resembles HIV via point mutations in the
Gag protein (Rhee and Hunter, 1990). Moreover, HIV-1 Gag
can be induced to spontaneously assemble in vitro into protein
Cell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc. 551
Cell Host & Microbe
Reviewspheres of the correct size in the presence of simple chemicals
and nucleic acid (Campbell et al., 2001). Thus, the ability tomulti-
merize into approximately spherical particles appears intrinsic to
Gag proteins in general, and divergence in retrovirus morpho-
genesis pathways likely reflects only quantitative differences in
the requirement for a membrane ‘‘scaffold.’’
Given that HIV-1 Gag can assemble into complete spheres in
the absence of membrane in vitro, yet is only observed to
assemble into spheres on membranes in vivo, key questions
(that remain unanswered) are (1) the degree to which HIV-1 Gag
preassembles into oligomeric arrays prior to membrane binding
under physiological conditions and (2) how HIV-1 Gag moves to
sites on membranes where particle assembly becomes observ-
able (Figure 1B). Thesequestions are potentially related, because
the multimeric state adopted by Gag in the cytoplasm could
present different cell biological problems in terms of its intracel-
lular transport. Gag monomers could likely diffuse freely through
the cytoplasm to sites of assembly on cell membranes, while
partly preassembled capsids or Gag oligomers might require
active transport to membranes for envelopment, particularly if
they are associated with viral RNA. In principle, it is possible
that HIV-1 Gag remains entirely monomeric or, alternatively,
forms low-order multimers prior to engagement of a cell me-
mbrane. In solution in vitro, Gag can exist in a monomer-dimer
or monomer-trimer equilibrium, depending on conditions (Datta
et al., 2007), but this parameter is obviously difficult to measure
in the cytoplasm of cells. Other observations that suggest that
some degree of Gag oligomerization occurs in the cytoplasm
prior to membrane binding include the findings that membrane-
binding defective Gag proteins can be incorporated into virions
(Yuan et al., 1993) and that HIV-1 Gag deletion mutants that
cannot multimerize are poor membrane-binding proteins in cells
(Sandefur et al., 1998). Moreover, the efficiency with which Gag
Figure 1. Assembly of the HIV-1 Gag Protein
(A) A hypothetical structural representation of the HIV-1 Gag protein in
extended conformation, assembled from the known structures of the isolated
MA (green), CA (red), and NC (blue) domains. Sequences of unknown structure
or putatively flexible regions are colored gray.
(B) Some possible modes of HIV-1 Gag addition to an assembling viral particle.
Whether Gag assembles into low-order oligomers or engages membrane prior
to joining the growing Gag sphere is unknown. Also unknown is the location
where Gag first engages viral RNA.associates with cell membranes is dependent on its intracellular
concentration (Perez-Caballero et al., 2004). However, none of
these findings refute the possibility that Gag monomers are
added to a growing membrane-associated protein shell, one
monomer at a time. Under either scenario, Gag multimerization
would favor stable membrane association (Figure 1).
Studies employing fluorescence recovery after photobleach-
ing and photoactivation techniques indicate the presence of
a population of Gag molecules that are diffusely distributed in
the cytoplasm and can move throughout the cytoplasm within
minutes (Gomez and Hope, 2006). This population is reasonably
assumed to represent Gag molecules that are yet to assemble
into complete particles. However, at present it is not clear
whether this diffuse pool represents Gag monomers or oligo-
mers and whether its rapid movement represents diffusion or
requires active transport. Several retroviral Gag proteins have
been reported to bind to the microtubule-associated motor
protein, KIF4, and KIF4 has been reported to be required for
HIV-1 assembly (Martinez et al., 2008). Nonetheless, it is also
true that pharmacological ablation of microtubules or the
actin cytoskeleton has little or no effect on the accumulation of
HIV-1 Gag at the plasma membrane or the yield of virion parti-
cles, suggesting that active transport of Gag is not required for
particle assembly (Jouvenet et al., 2006). Other studies suggest
that specific host proteins involved in intracellular transport—for
example, the GGA and Arf proteins—are also required for Gag
movement to the plasma membrane (Joshi et al., 2008). Overall,
the behavior of Gag and requirements for interactions with host
machinery in the cytoplasm of cells prior to its engagement of
membranes and incorporation into assembling particles remain
incompletely defined.
The identity of the cell membrane that provides sites for the
completion of HIV-1 particle assembly has been somewhat
controversial in recent years. The canonical view that the plasma
membrane served as the site for retroviral assembly was chal-
lenged by several studies that demonstrated considerable
amounts of HIV-1 Gag protein and/or mature virion particles in
late endosomes (Nydegger et al., 2003; Pelchen-Matthews
et al., 2003; Sherer et al., 2003). These findings suggested that
Gag was initially targeted to late endosomal membranes, that
virions were formed by budding into the endosomal lumen,
and that extracellular particles were liberated via an endo-
some-based secretory pathway. Part of the attractiveness of
the notion that HIV-1 particle assembly occurs at endosomes
came from the fact that virion budding requires the ESCRT
proteins, which normally mediate the budding of vesicles into
the late endosomal lumen (Bieniasz, 2006; Morita and Sund-
quist, 2004). Indeed, the Hrs protein, which targets endosomal
membranes to nucleate the recruitment of ESCRT proteins, is
effectively mimicked by HIV-1 Gag, as both proteins encode
PTAPmotifs that recruit ESCRT-I to enable budding events (Por-
nillos et al., 2003). Apparent HIV-1 assembly in endosomes ap-
peared especially prominent inmacrophages, in which very large
numbers of virion particles are found within compartments
containing late endosomal markers (Pelchen-Matthews et al.,
2003). Although intracellular particle assembly was initially
thought to be a unique feature of macrophages, similar studies
reporting localization of HIV-1 Gag and virions in endosomal
compartments in fibroblast, epithelial, and T lymphocyte cell
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assembly is initiated on endosomal membranes in all cell types
(Nydegger et al., 2003; Sherer et al., 2003).
Several more recent studies strongly suggest that HIV-1
assembly occurs at the plasma membrane. First, newly synthe-
sized Gag appears first at the plasmamembrane and only later in
endosomes (Finzi et al., 2007; Harila et al., 2006; Jouvenet et al.,
2006; Neil et al., 2006; Rudner et al., 2005). Second, the appear-
ance of Gag in endosomes can be inhibited by inhibiting endocy-
tosis without affecting the yield of extracellular particles. Third,
pharmacological manipulations that block endosomemovement
(such as disruption of cytoskeleton or Rab protein recruitment to
late endosomes) do not affect Gag appearance at the plasma
membrane or particle release. Fourth, rational targeting of Gag
by replacement of the MA globular head with specific membrane
targeting protein domains results in extracellular particle forma-
tion when Gag is targeted to the plasma membrane. Conversely,
when Gag is deliberately targeted to endosomal membranes,
particles form in the late endosomal lumen but do not leave the
cell (Jouvenet et al., 2006). Overall, these data strongly suggest
that HIV-1 assembly occurs at the plasma membrane and that
the appearance of Gag and or viral particles in endosomes can
occur as a result of endocytosis, following a failure to complete
budding or adherence of the completed virion particle to the in-
fected cell surface.
Recently developed approaches that allow direct observa-
tions of HIV-1 Gag protein and particle assembly in real time
have confirmed that HIV-1 assembly occurs primarily at the
plasma membrane. Improvements in microscopic techniques
and the application of Gag-fluorescent fusion proteins that
accurately recapitulate the assembly process have made this
possible. Indeed, elegant correlative fluorescence/electron mi-
croscopy studies employing Gag-GFP proteins have allowed
the demonstration that fluorescent puncta at the plasma me-
mbrane represent bona fide, individual VLPs that are released
into the extracellular milieu (Larson et al., 2005). Additionally,
total internal reflection microscopy is ideally suited for imaging
assembly events, and recent imaging studies using this tech-
nique have permitted direct observation and quantitative anal-
ysis of the assembly of individual HIV-1 particles in real time in
living cells (Jouvenet et al., 2008). For example, it has been
possible to determine that an individual HIV-1 VLP assembles
over 5 min under optimal conditions. Moreover, optical tech-
niques have been developed that document the irreversible
completion of virion assembly and the ESCRT-protein-mediated
scission of the nascent virions from cells (Jouvenet et al., 2008).
In principle, elaborations of single-particle analysis might allow
imaging of the recruitment of other virion components such as
genomes and as such allow a more complete picture of the
temporal sequence of events that occur during HIV-1 virion
formation.
Macrophages were often thought to represent a special envi-
ronment for HIV-1 assembly, because intracellular virions were
particularly prominent therein (Pelchen-Matthews et al., 2003).
Nonetheless, in this cell type, too, productive HIV-1 assembly
occurs at the plasma membrane (Jouvenet et al., 2006).
However, large areas of the macrophage plasma membrane
are sequestered within the cell, forming an intracellular pseudo-
compartment, which upon sectioning and electron microscopic552 Cell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc.analysis has the appearance of a bona fide intracellular compart-
ment. Importantly, this ‘‘compartment’’ is accessible to exter-
nally applied membrane-impermeant stains and is bounded by
plasma membrane that is continuous with the conventional
plasma membrane. These deeply invaginated pseudocompart-
ments often contain virions that are either completely assembled
or in the process of assembly (Deneka et al., 2007; Welsch et al.,
2007). Because virions assembled in the plasma membrane-
bounded intracellular pseudocompartments would inherently
tend to become trapped and accumulate therein, virions inevi-
tably appear enriched at intracellular sites as compared to the
conventional plasma membrane upon electron microscopic
analysis. These intracellular pseudocompartments may repre-
sent favored sites for HIV-1 assembly, but it is not currently clear
whether they are static or dynamic or whether they represent
exocytic, endocytic, or phagocytic intermediates.
Because the plasma membrane represents only a tiny fraction
of the total membrane content of the cell, a conceptual problem
was explaining how this membrane is selected for HIV-1
assembly. Recent findings have defined an underlying mecha-
nism. Specifically, it appears that a plasma membrane resident
phosphoinositide, namely PI(4,5)P2, is specifically recognized
by the globular head of the MA domain of Gag (Saad et al.,
2006). Concordantly, overexpression of 5-phosphatase IV,which
depletes cellular PI(4,5)P2, redirects HIV-1 assembly away from
the plasma membrane to internal membranes (Ono et al.,
2004), and Gag binds preferentially to liposomes containing
PI(4,5)P2 (Chukkapalli et al., 2008). Notably, an NMR structure
of the HIV-1 MA domain, in complex with an analog of
PI(4,5)P2, reveals that the PI(4,5)P2 adopts a highly unusual
extended conformation, whereby one of the acyl chains is flipped
out from the plane of the membrane so that it and the phosphoi-
nositide head group bind to a cleft in the matrix globular head
(Saad et al., 2006). Meanwhile, the remaining acyl chain remains
embedded in the plasma membrane. Importantly, while the
N-terminal myristoyl moiety of HIV-1 Gag is sequestered in
a hydrophobic pocket when Gag is monomeric and in solution,
the interaction between MA and PI(4,5)P2 induces a conforma-
tional change in MA favoring myristate exposure. Thus, the
HIV-1 MA domain effectively has a tripartite membrane interac-
tion domain consisting of the N-terminal myristate, a cluster of
basic amino acids, and a hydrophobic groove that binds the flip-
ped out PI(4,5)P2 acyl chain. Because myristate exposure and
increased membrane-binding affinity are also favored by Gag
multimerization (Tang et al., 2004), a series of protein-protein
and protein-lipid interactions likely cooperate to correctly target
and stabilize Gag interaction specifically with the plasma
membrane during particle assembly.
Overall, the recent findings are consistent with a model in
which Gag monomers and/or low-order multimers diffuse or
are transported throughout the cell cytoplasm until they
encounter either or both PI(4,5)P2 and a growing Gag protein
shell at the plasma membrane. Thereafter, the intrinsic sphere-
forming properties of the Gag protein drive the assembly of the
nascent virion particle.
The Mechanism of HIV-1 Budding
The intrinsic propensity of Gag to assemble into spheres on
PI(4,5)P2-containing membrane surfaces is sufficient to initiate
Cell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc. 553
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some years it has been clear that HIV-1 and other retroviruses
encode late-budding or L domains that bind directly or indirectly
to components of the ESCRT pathway in order to complete
assembly and separate the nascent virion envelope from cell
membranes (Bieniasz, 2006; Morita and Sundquist, 2004)
(Figure 2). Failure to recruit the ESCRT pathway to sites of viral
assembly results in the formation of nearly complete immature
particles whose envelope remains continuous with the host cell
plasma membrane in a lollipop-like configuration. In the case
of HIV-1, the L domains are encoded within the p6 domain of
Gag and consist of peptide sequences PTAP andYPLTSL, which
bind Tsg101 (a component of ESCRT-I) and ALIX (an ESCRT-I-
and ESCRT-III-binding protein), respectively (Bieniasz, 2006;
Morita and Sundquist, 2004). The ESCRT proteins have been
an active area of research in recent years—many aspects of
protein structure and function have been elucidated and recently
reviewed in detail by others (Hurley and Emr, 2006; Raiborg and
Stenmark, 2009). Essentially, the originally described functions
of the ESCRT pathway were to (1) select transmembrane protein
cargos (generally those tagged by ubiquitination) and sort them
into specified areas of endosomal membranes, (2) induce
membrane invagination away from the cytoplasm and toward
the endosomal lumen, and (3) fuse the neck of the induced
membrane invagination to generate a vesicle within the endoso-
mal lumen. Recruitment of the ESCRT pathway to endosomal
membranes in mammalian cells is mediated largely by the Hrs/
STAM complex, which can be loosely viewed as a cellular ortho-
log of HIV-1 Gag in that it has a specific membrane-binding
domain and recruits ESCRT-I, in part through a PTAP motif
that binds to Tsg101 (Pornillos et al., 2003).
The ESCRT pathway is the only known cellular machinery that
is capable of severing a membranous neck when the cytoplasm,
and therefore the machinery itself, has access only to the interior
of the neck. A key current challenge is the elucidation of how
Figure 2. Recruitment of the Mammalian ESCRT Machinery to
Various Subcellular Locations by Different Host and Viral Proteins
HIV-1 Gag and the host proteins Hrs and Cep55 each recruit ESCRT-I and/or
ALIX to mediate topologically equivalent membrane fission reactions required
for viral budding, multivesicular body formation, and cell division. The ESCRT
machinery may also be required for completion of autophagy.a cellular machinery that is configured in this way is capable of
mediating membrane fission, thereby causing the release of
a budding HIV-1 particle. However, clues from studies of the
normal cellular function of the ESCRT pathway and some
in vitro studies have provided significant insight. Aside from the
generation of endosomal vesicles, there are few cell functions
that require such membrane fission reactions, and recently the
ESCRT pathway has been implicated directly or indirectly in
each of these. Specifically, Cep55, a mammalian protein that
localizes to the midbody during cell division and is known to
be required for the completion of abscission, has been shown
to recruit Tsg101, ALIX, and ultimately other ESCRT proteins to
the midbody, where they are required for the completion of cell
division (Carlton and Martin-Serrano, 2007; Morita et al., 2007).
Thus, HIV-1 Gag, Hrs, and Cep55 all share the ability to directly
recruit ESCRT proteins and thereby induce the fission of cyto-
plasm-filled membranous stalks (Figure 2).
Although the ESCRT pathway is quite elaborate and serves
multiple functions in modern eukaryotes, a surprising recent
finding is that a rudimentary ESCRT pathway, comprising four
ESCRT-III homologs and a VPS4 ATPase, is present in some
Archea, including the genus Sulfolobus (Samson et al., 2008).
These ESCRT-III-like proteins localize to sites of membrane
ingression and appear to be required for cell division in Sulfolo-
bus. Given these findings, and because Archea lack an endo-
membrane system, it is likely that facilitating cell division is the
ancestral function of the ESCRT pathway. In eukaryotes, the
ESCRT pathway has evidently elaborated and acquired addi-
tional components, presumably to take on new functions. It is
these elaborations of the ESCRT pathway, including the
ESCRT-I complex and ALIX, that HIV-1 and other viruses have
learned to recruit in order to parasitize the membrane fission
activity of the ESCRT pathway, but the elaborations do not
appear to be universally required for viral budding. Rather, they
appear to be exploited by viruses like HIV-1 simply to access
the core fission machinery (Bieniasz, 2006; Morita and Sund-
quist, 2004) (Figure 2).
Because ESCRT-III and VPS4 appear to constitute theminimal
form of the ESCRT pathway, together they should constitute this
required minimal membrane fission machinery. This prediction
appears to be quite accurate, and several in vitro and in vivo
studies have demonstrated properties of the ESCRT-III complex
and its components that lead to plausible models of how
ESCRT-III proteins and VPS4 might induce membrane fission.
For example, overexpression of the ESCRT-III component
CHMP4/Snf7 in mammalian cells leads to the formation of
curved filaments on the cytoplasmic face of the plasma
membrane, in an approximately circular array (Hanson et al.,
2008). Moreover, CHMP4/Snf7 coexpression with dominant-
negative VPS4 results in membranous protrusions from the cell
surface, with circular arrays of CHMP4 and associated VPS4
accumulated at the base of the protrusions (Hanson et al.,
2008). Additionally, in vitro experiments employing CHMP2/
VPS2 and CHMP3/VPS24 show that truncated and thereby
putatively activated forms of these proteins can assemble into
helical tubes, with basic membrane-binding surfaces on the
exterior and VPS4-binding domains on the interior of the tube
(Lata et al., 2008b). Accordingly, assembly of the helical tubes
in the presence of VPS4 results in the localization of VPS4 in
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These aforementioned studies suggest a model in which
ESCRT-III proteins assemble into circular filaments and/or
helical bands within or proximal to the membranous neck that
is to be severed. Thereafter, VPS4 ESCRT-III subunits could
sequentially remove individual subunits of the filaments and/or
bands, thereby constricting the neck until it ultimately fuses
with itself (Figure 3A).
However, a detailed analysis of the ESCRT-III complex in
yeast provides additional insights and invokes different and
discrete roles for the various subunits in ESCRT-III function (Sak-
sena et al., 2009; Teis et al., 2008). The yeast ESCRT-III assem-
bled on endosomal membranes has a measured mass of
approximately 450 kDa, and biochemical and genetic studies
suggest that it is assembled in a particular order (Saksena
Figure 3. Models for Membrane Scission by ESCRT-III Proteins
(A) Concentric rings of CHMP6/VPS20, CHM4P/Snf7, and CHMP2/VPS2-
CHMP3/VPS24 form at the base and/or within the membranous neck.
VPS4-induced sequential removal of individual CHMP proteins constricts
the rings, ultimately closing the neck.
(B) A single CHMP6/VPS20 subunit nucleates the recruitment of CHMP4/Snf7
subunits, which oligomerize to form a filament that is capped by CHMP3/
VPS24,which then recruitsCHMP2/VPS2.Subsequent removal ofCHMP4/Snf7
subunits, catalyzed by VPS4, progressively constricts the ring-like filament.
(C) A single CHMP6/VPS20 subunit nucleates the oligomerization of a CHMP4
protein filament that inwardly spirals as it elongates and is capped by CHMP3/
VPS24 and CHMP2/VPS2. This model differs from (A) and (B) in that VPS4 is
required only for the recycling of the ESCRT-III subunits (adapted from and/or
inferred by data from Hanson et al., 2008; Lata et al., 2008b; Saksena et al.,
2009; Teis et al., 2008; Wollert et al., 2009; see text for details).554 Cell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc.et al., 2009; Teis et al., 2008). Specifically, a single CHMP6/
VPS20 subunit nucleates the recruitment of CHMP4/Snf7
subunits, which oligomerize to form a filament that eventually
reaches 10–15 molecules in length. The filament is capped by
CHMP3/VPS24, which then recruits CHMP2/VPS2, which in
turn recruits VPS4. In this model, the subsequent and sequential
removal of CHMP4/Snf7 subunits, catalyzed by VPS4, would
again progressively constrict a ring-like filament, ultimately
driving fission of the membranous neck (Figure 3B).
A third model for membrane fission is invoked by a recent
study that has shown that the addition of pure recombinant yeast
ESCRT-III proteins to so-called giant unilamellar vesicles (GUVs)
is sufficient to generate vesicles within GUVs (Wollert et al.,
2009). These vesicles become separated from the GUV-limiting
membrane, contain medium that was outside the GUV at the
beginning of the experiment, and therefore can be regarded as
analogous to extracellular enveloped viral particles or the intralu-
menal vesicle of MVBs. Notably, CHMP6/VPS20, CHMP4/Snf7,
and CHMP3/VPS2 were each required for optimal formation of
vesicles within GUVs, but CHMP2/VPS2 and VPS4 were
dispensable. Rather, CHMP2/VPS2 and VPS4 appeared to be
required for removal of the ESCRT proteins from the GUV-
limitingmembrane only after fission, thereby permitting a second
round of intralumenal vesicle generation. A model that arises
from this study invokes a CHMP protein filament, which inwardly
spirals as it elongates, as the driver of membrane fission (Wollert
et al., 2009) (Figure 3C).
Although these models are somewhat speculative and contra-
dictory in some of their aspects, a key concept that is shared
among them is that the CHMP proteins exist in solution in an
autoinhibited conformation and that recruitment of a CHMP
monomer to a growing array or filament on a membrane surface
is accompanied by conformational ‘‘activation,’’ revealing
binding sites for the next CHMP protein monomer to be recruited
(Lata et al., 2008a; Zamborlini et al., 2006). Thus, it is possible
that monomeric CHMP proteins exist in a metastable conforma-
tion and provide the energy for membrane fission simply as
a result of their binding to membrane and other CHMP proteins
at the site of membrane fission. In such a scenario, VPS4 could
be required to effectively ‘‘reload’’ the CHMP proteins, re-estab-
lishing their metastable conformation, or to remove CHMP
proteins to bring membranes together. Clearly, further experi-
mentation will be required to firmly establish which, if any, of
the models that have been proposed (Figure 3) approximate
the actual events that induce membrane fission. These studies
are key to understanding not only howHIV-1 and other viral parti-
cles are released from cells but also how cell division and multi-
vesicular body formation are completed, and they will highlight
one of the most striking examples of how viruses parasitize
host machinery to facilitate their replication.
Tetherin, a Host Inhibitor of Virus Particle Release,
and Its Antagonism by HIV-1 Accessory Proteins
Following the ESCRT protein-mediated scission of virion and cell
membranes, it would appear inevitable that an HIV-1 virion or
any enveloped virion particle would be free to diffuse into the
extracellular milieu and disseminate to infect other cells.
However, recent findings have shown that the host cell can inter-
vene at this step and block the release of virion particles. These
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Reviewfindings are based on the earlier studies that revealed that HIV-1
constructs in which the vpu genewas ablatedwere poorly able to
generate extracellular particles when introduced into certain so-
called ‘‘nonpermissive’’ cell types (Klimkait et al., 1990; Terwil-
liger et al., 1989). The HIV-1 Vpu protein consists of two major
elements: an N-terminal transmembrane domain that anchors
Vpu in cellular membranes and a cytoplasmic tail consisting of
two putative a helices separated by a conserved casein kinase
II phosphorylation site. The transmembrane domain was known
to be critical for enhancing particle release from nonpermissive
cells, while the cytoplasmic tail was thought to be less important
(Schubert et al., 1996). Notably, heterokaryon studies suggested
that Vpu acts by antagonizing a host restriction activity that
impedes HIV particle release (Varthakavi et al., 2003).
While the nature of the inhibitory activity remained undefined
for several years, electron microscopy studies showed that
HIV-1 particles generated in the absence of Vpu accumulated
in a mature form at the plasma membrane and in intracellular
compartments of nonpermissive cells (Go¨ttlinger et al., 1993;
Klimkait et al., 1990; Terwilliger et al., 1989). The appearance
of HIV-1 Vpu-defective particles in internal membrane-bound
compartments was suggestive of a Gag membrane targeting
defect or a defect in the endosome-based secretory pathway
that had been proposed to be the mechanism by which assem-
bled or assembling HIV-1 particles gained access to the extra-
cellular milieu (Nydegger et al., 2003; Sherer et al., 2003).
However, later studies showed that the intracellular virions that
accumulated in the absence of Vpu arose primarily as a conse-
quence of their internalization from the plasmamembrane (Harila
et al., 2006; Neil et al., 2006). Thus, the primary defect induced by
the absence of Vpu in nonpermissive cells occurred at the cell
surface rather than at intracellular locations.
Importantly, the defect in particle release that occurred as
a consequence of Vpu deficiency in nonpermissive cells was
distinct from that associated with late-domain mutations that
cause a failure to recruit the ESCRT machinery (Go¨ttlinger
et al., 1993; Klimkait et al., 1990; Neil et al., 2006; Terwilliger
et al., 1989). In the case of L domain mutations, continuity
between viral and cellular membrane was maintained, and
incompletely formed immature virions accumulate at the plasma
membrane. Conversely, in the absence of Vpu, virions were fully
formed and mature and, in contrast to virions retained as
a consequence of L domain defects, could be liberated from
the cell by protease (Neil et al., 2006). Thus, the absence of
Vpu caused a very late block in the release of HIV-1 particles,
after the completion of viral particle assembly. The putative
inhibitor appeared to consist of protein-based tethers that re-
tained compete virions on the surface of cells from where they
might be internalized.
Importantly, the finding that cells that were otherwise permis-
sive for the release of Vpu-defective HIV-1 virions could be
rendered nonpermissive by treatment with IFNa suggested
that the activity was a component of the IFN-induced innate
immune response (Neil et al., 2007). Recently, a protein that
exhibits most or all of the properties expected of the putative
inhibitor has been identified and dubbed ‘‘tetherin’’ (Neil et al.,
2008; Van Damme et al., 2008). Tetherin is an IFN-induced inte-
gral membrane protein (previously called BST-2, CD317, or
HM1.24) that has a unique topology; it is composed of a shortN-terminal cytoplasmic tail linked to a transmembrane anchor
and an extracellular domain that is predicted to form a coiled
coil. Tetherin also possesses a putative glycophosphatidylinosi-
tol lipid anchor at its C terminus and is therefore highly unusual
among membrane-associated proteins in harboring two
completely different types of membrane anchor. Crucially,
ectopic expression of tetherin in cells that would otherwise be
tetherin-negative is sufficient to induce protease-sensitive teth-
ering of Vpu-defective HIV-1 particles on the surface of infected
cells. A proportion of the tethered virions are internalized via
a Rab5-dependent pathway and accumulate in late endosomal
compartments (Neil et al., 2006, 2008). Prototype ‘‘nonpermis-
sive cells’’ (e.g., HeLa) constitutively express tetherin, and teth-
erin depletion from HeLa cells markedly increases the yield of
extracellular particles generated by Vpu-defective proviral
constructs (Neil et al., 2008; Van Damme et al., 2008). As was
earlier predicted, virions whose release was blocked as a conse-
quence of tetherin expression are fully formed and mature and
have lipid bilayers that are discontinuous with cell membranes
(Neil et al., 2008).
Although the precise mechanism by which tetherin acts is yet
to be elucidated, the fact that it consists of a coiled coil with
a membrane anchor at either end suggests the possibility that
it simply crosslinks cell membranes and virion envelopes
(Figure 4). Tetherin is also known to form dimers, but it is not
known whether this property is essential for virion retention.
Consistent with the idea that tetherin is a direct physical compo-
nent of the protein-based tethers that retain virions, it colocalizes
with virions on the surface of infected cells and within endo-
somes following virion internalization (Jouvenet et al., 2009;
Neil et al., 2008; Van Damme et al., 2008).
Clearly, Vpu acts as a viral antagonist of tetherin. Indeed, teth-
erin dramatically inhibits the release of Vpu-defective HIV-1
virions but has only modest effects on wild-type Vpu-expressing
HIV-1. Moreover, Vpu colocalizes with tetherin in intracellular
compartments, including the trans-golgi network, and in so
doing prevents the colocalization of tetherin with nascent virions
(Dube et al., 2009; Jouvenet et al., 2009; Neil et al., 2008). Vpu
also causes downregulation of tetherin from the cell surface
and reduces the total level of tetherin in cells, at least under
conditions of transient overexpression (Bartee et al., 2006; Van
Damme et al., 2008). Vpu-induced reduction in tetherin steady-
state levels is reversed by proteasome inhibitors (Goffinet
et al., 2009), but since proteasome inhibition can deplete ubiqui-
tin and thereby affect the trafficking of some cargoes through the
endosomal system, it is not completely clear whether the protea-
some is directly responsible for tetherin degradation. Moreover,
one recent study has claimed that tetherin downregulation from
the cell surface does not occur in some T cell lines in which Vpu is
capable of stimulating particle release (Miyagi et al., 2009). Thus,
the role of tetherin downregulation in Vpu activity is uncertain at
present, and defining precisely how Vpu antagonizes tetherin
remains a pressing question in this area.
Notably, early studies suggested that release of diverse retro-
viruses as well as filoviruses from nonpermissive cells could be
enhanced by Vpu coexpression (Go¨ttlinger et al., 1993; Neil
et al., 2007), leading to the prediction that tetherin has a rather
broad antiviral specificity. This prediction has proved to be
accurate, as tetherin has been recently shown to block theCell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc. 555
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(Jouvenet et al., 2009; Kaletsky et al., 2009; Sakuma et al.,
2009). Moreover, other viruses have clearly evolved to antago-
nize tetherin activity—the KSHV K5 protein is capable of
inducing tetherin degradation (Bartee et al., 2006), and the Ebola
virus glycoprotein associates with tetherin and antagonizes its
antiviral function (Kaletsky et al., 2009). Recent findings have
also demonstrated that simian immunodeficiency viruses,
which, for the most part, do not encode Vpu proteins, can use
Nef proteins to antagonize tetherin (Jia et al., 2009; Zhang
et al., 2009).
As is the case with other restriction factors that inhibit retro-
virus replication, tetherin has been evolving under positive selec-
tion in primates (McNatt et al., 2009). In fact, tetherin proteins
frommacaques and African greenmonkeys are capable of inhib-
iting HIV-1 particle release but are insensitive to antagonism by
HIV-1 Vpu. Conversely, human tetherin is comparatively insensi-
tive to antagonism by several SIV Nef proteins (Jia et al., 2009;
Zhang et al., 2009). The transmembrane domain of tetherin
defines this species-specific difference in sensitivity to HIV-1
Vpu, and the introduction of two mutations in the human tetherin
protein transmembrane domain that correspond to sequences
found in macaque tetherin is entirely sufficient to generate
a tetherin protein that is completely resistant to antagonism by
HIV-1 Vpu (McNatt et al., 2009). Similarly, a five amino acid dele-
tion in the cytoplasmic tail of human tetherin is responsible for its
resistance to SIV Nef proteins (Jia et al., 2009; Zhang et al.,
2009). Strikingly, residues that contribute to determining the
sensitivity of tetherin to HIV-1 Vpu and SIV Nef coincide with
those that have been evolving under positive selection. Thus, it
is likely that past selection pressures imposed by viral antago-
nists of tetherin, perhaps including Vpu-like proteins, have deter-
mined the range of species in which modern HIV-1 and SIV Vpu
and Nef proteins are able to function.
Remarkably, a second candidate for a molecule that imposes
a requirement for Vpu in the release of HIV-1 particles, termed
CAML, has been reported (Varthakavi et al., 2008). Like tetherin,
Figure 4. Model for Virion Retention by
Tetherin
This model invokes tetherin incorporation into the
virion envelope; a variety of orientations of the
molecule are possible. Virions are tethered to
each other as well as to the cell surface, and
tethering can lead to virion internalization. Vpu
sequesters tetherin from sites of particle assembly
and induces its removal from the cell surface.
expression of CAML in otherwise per-
missive cells was reported to render
them nonpermissive, and RNAi-mediated
CAML depletion was reported to have the
reciprocal effect. These observations are
somewhat perplexing, as it is difficult to
envision how two different molecules
can be both necessary and sufficient to
define the difference between permissive
and nonpermissive cells. While it is
possible that CAML and tetherin might
both contribute to the retention of virions by nonpermissive cells,
further experimentation is needed to clarify the role of each
protein in imposing the requirement for Vpu in HIV-1 particle
release.
Concluding Remarks
The recent studies reviewed above have significantly enhanced
our understanding of some of the cell biological aspects of HIV-1
assembly and release. However, there are a number of signifi-
cant questions that arise from these findings, as well as addi-
tional questions that have proved to be somewhat intractable
thus far. For example, various specific pre-existing domains in
the plasma membrane, such as lipid rafts, tetraspanin-enriched
domains, or sites of cell-to-cell contact, have been reported to
be favored target sites for HIV-1 assembly (Hu¨bner et al., 2009;
Jolly and Sattentau, 2005; Nguyen and Hildreth, 2000; Nydegger
et al., 2006; Ono and Freed, 2001), and what role the PI(4,5)P2-
binding properties of Gag or putative active Gag transport plays
in this apparent selectivity is unclear. Moreover, ubiquitin and
ubiquitin ligases appear capable of stimulating HIV-1 particle
budding, but it is not clear how (Chung et al., 2008; Usami
et al., 2008). Finally, we do not fully understand how other viral
components are incorporated into virions: where does viral
RNA first interact with Gag, and how does viral RNA move within
the cell and find its way to sites of particle assembly? How are
envelope proteins specifically incorporated into virions while at
the same time pseudotyping can be so promiscuous (Jorgenson
et al., 2009)?
Overall, it is notable how a superficially simple process—the
assembly of a few proteins, RNA, and lipids into a particle that
is released from cells—can, upon closer examination, turn out
to be remarkably complex and interesting from a cell biological
perspective. While important details of HIV-1 particle genesis
have been revealed by recent work, achieving a nearly complete
understanding of the cell biology of HIV-1 particle assembly,
budding, and release will surely occupy scientists for the fore-
seeable future.556 Cell Host & Microbe 5, June 18, 2009 ª2009 Elsevier Inc.
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